Business Context and Reporting Period
This Form 6-K filing by EUDA Health Holdings Ltd covers the month of October 2025, with the report dated October 3, 2025. The filing details amendments to a convertible promissory note purchase agreement entered into with an institutional investor in August 2025.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or overall debt levels. The only specific financial figures disclosed relate to the convertible note transaction:
- Total Note Capacity: Up to $10,000,000.
- Initial Note Issued (August Note): $1,000,000 principal amount.
- Amount Converted to Date: $837,500 (converted into 569,859 ordinary shares).
- Remaining Note Balance: $162,500.
- Shares Delivered in September: 41,620 ordinary shares at $0.901 per share.
Material Changes
The primary material change is the execution of an amendment to a Letter Agreement on October 2, 2025, regarding the remaining $162,500 balance of the August Note. Key changes include:
- Conversion Restriction: The Purchaser agreed not to convert the remaining balance until after October 31, 2025.
- Repayment Date Options: On the Repayment Date (October 31, 2025), the Purchaser may either:
- Convert the $162,500 balance into 81,250 ordinary shares at a fixed price of $2.00 per share.
- Request cash repayment of the $162,500 on or before November 17, 2025.
- Future Issuance: The Company confirmed it does not intend to exercise its right to request the sale of additional Notes under the original Purchase Agreement.
Outlook, Risks, and Management Commentary
Management commentary is limited to the specific terms of the note amendment. The filing highlights a potential liquidity event on November 17, 2025, if the investor elects cash repayment. There is no broader guidance provided regarding future revenue, operational outlook, or general risk factors in this specific report.
Investor Verification Checklist
- Verify the Company's current cash position to determine ability to repay the $162,500 if the investor elects cash repayment by November 17, 2025.
- Confirm the total number of outstanding ordinary shares post-conversion to assess potential dilution impact.
- Review the full text of the Amendment to the Letter Agreement (Exhibit 1.1) for any additional covenants or conditions not summarized here.
- Monitor the Company's stock price relative to the $2.00 conversion threshold mentioned in prior agreements, although the current amendment sets a fixed conversion price.